A tissue repair fibrous membrane, preparation method and application thereof, and tissue repair product. The tissue repair fibrous membrane is formed by interweaving fiber filaments having a diameter of 10 nm to 100 μm, and has pore structures formed by interweaving between the fiber filaments. The fiber filaments have concave structures, and have annular convex structures thereon in the radial direction of the filaments.

A method and kit for stopping cerebrospinal fluid (CSF) leaks, comprising penetrating and passing through a dural tissue an applicator to access an interior dural space, injecting from the applicator a fibrinogen-containing solution into said dural space, applying a sealing member containing a fibrinogen polymerizing agent onto an exterior surface of the dural tissue, and forming a polymerized fibrinogen or polymerized fibrin clot by contacting the injected fibrinogen-containing solution and the fibrinogen polymerizing agent.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

A microneedle or microneedle device includes a microneedle body extending from a base to a penetrating tip formed from a silk fibroin based material, which is easy to fabricate and highly biocompatible. The microneedle device can include one or more microneedles mounted to a substrate. The silk fibroin can include active agents to be transported into or across biological barriers such as skin, tissue and cell membranes. The silk fibroin microneedles can be fully or partially biodegradable and/or bioerodible. The silk fibroin is highly stable, affords room temperature storage and is implantable. The silk fibroin structure can be modulated to control the rate of active agent delivery.

In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.

In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.

A fallopian biocompatible plug can include differently expandable portions. A method of treating a uterine abnormality of a patient includes: providing an endoscope having a working channel; inflating a uterine cavity with a fluid; delivering a biocompatible plug into an ostium of a fallopian tube of the patient, wherein the biocompatible plug is substantially cylindrical in form and configured to be radially expandable, wherein the biocompatible plug is configured to expand in the ostium of the fallopian tube to seal the fallopian tube from the uterine cavity; delivering a resection device through the working channel; and resecting the uterine abnormality.

A biologic material is disclosed. The biologic material comprises a crosslinked structural protein and macrophages seeded on the crosslinked structural protein. A method of use of the biologic material for an immunoregenerative treatment in a patient in need thereof also is disclosed. The method comprises steps of: (1) seeding the macrophages on the crosslinked structural protein, thereby obtaining the biologic material; and (2) implanting the biologic material into the patient.

The present invention is a specially prepared fibrin foam, and a method of (and equipment for) making it, which is flexible, contains either open cells, closed cells or both, and having individual cell diameters between 0.001 and 2 mm. Typical ratios of reactants, to give the desired foam characteristics, include 50 cc (45-55 cc) of whole blood (prior to separation to the plasma component) with the subsequent addition thereto of 2 ml (1.5-2.5 ml) 3% hydrogen peroxide, 5000 units (4500-5500 units) thrombin and 1 gm (0.9-1.1 g) calcium chloride in 3 cc (2-4 cc) water. The present invention also includes specialty vessels and constructs, namely, automated, or semi-automated inner containers for the non-blood reactants, and a custom outer separation vessel having a punted based with an annular base lip as well as an upper tube shape tapering inward towards its top annular opening.

The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.